151 related articles for article (PubMed ID: 32894784)
1. 28-day thawed plasma maintains α
Stettler GR; Moore EE; Huebner BR; Nunns GR; Moore HB; Coleman JR; Kelher M; Banerjee A; Silliman CC
Vox Sang; 2021 Feb; 116(2):181-189. PubMed ID: 32894784
[TBL] [Abstract][Full Text] [Related]
2. 14-Day thawed plasma retains clot enhancing properties and inhibits tPA-induced fibrinolysis.
Huebner BR; Moore EE; Moore HB; Shepherd-Singh R; Sauaia A; Stettler GR; Nunns GR; Silliman CC
J Surg Res; 2017 Nov; 219():145-150. PubMed ID: 29078874
[TBL] [Abstract][Full Text] [Related]
3. Effects of Blood Components and Whole Blood in a Model of Severe Trauma-Induced Coagulopathy.
Stettler GR; Moore EE; Nunns GR; Kelher M; Banerjee A; Silliman CC
J Surg Res; 2021 Mar; 259():55-61. PubMed ID: 33278796
[TBL] [Abstract][Full Text] [Related]
4. Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage.
Moore HB; Moore EE; Gonzalez E; Wiener G; Chapman MP; Dzieciatkowska M; Sauaia A; Banerjee A; Hansen KC; Silliman C
J Am Coll Surg; 2015 May; 220(5):872-9. PubMed ID: 25840538
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin-based oxygen carriers promote systemic hyperfibrinolysis that is both dependent and independent of plasmin.
Morton AP; Moore EE; Moore HB; Gonzalez E; Chapman MP; Peltz E; Banerjee A; Silliman C
J Surg Res; 2017 Jun; 213():166-170. PubMed ID: 28601310
[TBL] [Abstract][Full Text] [Related]
6. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
7. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage.
Bolliger D; Szlam F; Levy JH; Molinaro RJ; Tanaka KA
Br J Anaesth; 2010 Mar; 104(3):318-25. PubMed ID: 20133450
[TBL] [Abstract][Full Text] [Related]
8. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
9. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
[TBL] [Abstract][Full Text] [Related]
10. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839
[TBL] [Abstract][Full Text] [Related]
11. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
[TBL] [Abstract][Full Text] [Related]
12. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia.
Glueck CJ; Glueck HI; Tracy T; Speirs J; Stroop D
Metabolism; 1993 Nov; 42(11):1410-9. PubMed ID: 8231835
[TBL] [Abstract][Full Text] [Related]
13. Freeze-dried plasma enhances clot formation and inhibits fibrinolysis in the presence of tissue plasminogen activator similar to pooled liquid plasma.
Huebner BR; Moore EE; Moore HB; Sauaia A; Stettler G; Dzieciatkowska M; Hansen K; Banerjee A; Silliman CC
Transfusion; 2017 Aug; 57(8):2007-2015. PubMed ID: 28500652
[TBL] [Abstract][Full Text] [Related]
14. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
Nagai N; De Mol M; Lijnen HR; Carmeliet P; Collen D
Circulation; 1999 May; 99(18):2440-4. PubMed ID: 10318667
[TBL] [Abstract][Full Text] [Related]
15. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
16. PAI-1 and α2-AP in patients with morbid obesity.
Michalska M; Iwan-Ziętek I; Gniłka W; Dąbrowiecki S; Góralczyk B; Góralczyk K; Drela E; Rość D
Adv Clin Exp Med; 2013; 22(6):801-7. PubMed ID: 24431308
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
Watanabe R; Wada H; Miura Y; Murata Y; Watanabe Y; Sakakura M; Okugawa Y; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Shiku H; Nobori T
Clin Appl Thromb Hemost; 2001 Jul; 7(3):229-33. PubMed ID: 11441985
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque.
Robbie LA; Booth NA; Brown AJ; Bennett B
Arterioscler Thromb Vasc Biol; 1996 Apr; 16(4):539-45. PubMed ID: 8624776
[TBL] [Abstract][Full Text] [Related]
19. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
Opatrný K; Opatrná S; Vít L; Opatrný K
Am J Nephrol; 1998; 18(3):186-92. PubMed ID: 9627033
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs.
Lanevschi A; Kramer JW; Greene SA; Meyers KM
Am J Vet Res; 1996 Aug; 57(8):1124-30. PubMed ID: 8836361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
